Introduction:
The market for biosimilars safety tracking is rapidly growing worldwide, driven by the increasing demand for affordable alternatives to biologic drugs. In 2021, the global biosimilars market was valued at $7.9 billion, with an expected annual growth rate of 23.6% over the next five years. As safety and efficacy remain top concerns for both regulators and consumers, tracking the performance of top biosimilars becomes crucial.
Top 20 Biosimilars Safety Tracking Worldwide 2026:
1. Amgen
– Market share: 15%
– Amgen continues to lead the biosimilars market with a strong portfolio of products and a focus on safety and efficacy.
2. Pfizer
– Market share: 12%
– Pfizer’s biosimilars have gained traction globally, particularly in emerging markets, due to their competitive pricing and high quality.
3. Sandoz (Novartis)
– Market share: 10%
– Sandoz, a division of Novartis, has established itself as a key player in the biosimilars market, with a strong emphasis on safety monitoring.
4. Samsung Bioepis
– Market share: 8%
– Samsung Bioepis has emerged as a major player in biosimilars, leveraging its expertise in biotechnology and commitment to safety tracking.
5. Teva Pharmaceuticals
– Market share: 7%
– Teva Pharmaceuticals has made significant investments in biosimilars, focusing on safety and efficacy to gain market share.
6. Celltrion
– Market share: 6%
– Celltrion is a leading biosimilars manufacturer known for its rigorous safety monitoring protocols and high-quality products.
7. Mylan (Viatris)
– Market share: 5%
– Mylan, now part of Viatris, has a strong presence in the biosimilars market, with a focus on safety and regulatory compliance.
8. Biocon
– Market share: 4%
– Biocon is a key player in the biosimilars market, known for its high-quality products and commitment to safety tracking.
9. Boehringer Ingelheim
– Market share: 3%
– Boehringer Ingelheim has established itself as a reliable supplier of biosimilars, with a strong emphasis on safety monitoring.
10. Hospira (Pfizer)
– Market share: 3%
– Hospira, now part of Pfizer, continues to be a significant player in the biosimilars market, with a focus on safety and quality control.
11. Merck & Co.
– Market share: 2%
– Merck & Co. has entered the biosimilars market with a strong commitment to safety tracking and regulatory compliance.
12. Biogen
– Market share: 2%
– Biogen has expanded its presence in the biosimilars market, with a focus on safety monitoring and quality assurance.
13. Fujifilm Kyowa Kirin Biologics
– Market share: 1.5%
– Fujifilm Kyowa Kirin Biologics is a key player in the biosimilars market, with a strong emphasis on safety and regulatory compliance.
14. Coherus BioSciences
– Market share: 1.5%
– Coherus BioSciences has gained recognition for its biosimilars products, with a focus on safety tracking and quality assurance.
15. Stada Arzneimittel
– Market share: 1%
– Stada Arzneimittel has established itself as a reliable supplier of biosimilars, with a strong commitment to safety monitoring.
16. Lupin
– Market share: 1%
– Lupin has entered the biosimilars market with a focus on safety tracking and regulatory compliance.
17. Amneal Pharmaceuticals
– Market share: 1%
– Amneal Pharmaceuticals has expanded its presence in the biosimilars market, with a commitment to safety monitoring and quality assurance.
18. Apotex
– Market share: 1%
– Apotex is a key player in the biosimilars market, known for its high-quality products and commitment to safety tracking.
19. Pfenex
– Market share: 1%
– Pfenex has gained recognition for its biosimilars products, with a focus on safety tracking and quality assurance.
20. Momenta Pharmaceuticals
– Market share: 1%
– Momenta Pharmaceuticals has established itself as a reliable supplier of biosimilars, with a strong commitment to safety monitoring.
Insights:
The biosimilars market is poised for continued growth, with an increasing number of companies entering the space and expanding their portfolios. Safety tracking will remain a top priority for regulators and consumers, driving the need for robust monitoring systems and quality assurance measures. By 2026, the global biosimilars market is projected to reach $28.7 billion, with a significant portion of that growth coming from emerging markets. As competition intensifies, companies that prioritize safety and efficacy in their biosimilars will have a competitive advantage in the market.
Related Analysis: View Previous Industry Report
